
usd feb pm et
summari compani develop manufactur market medic equip treatment
diagnosi sleep-disord breath
nm price-to-earnings oper ep
risk assess reflect view highli
competit natur respiratori market includ
low barrier entri see potenti
addit price pressur product due
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan stock trade
follow sale growth jun
forecast revenu rise
new product
grow public awar sleep-disord
opportun grow focu
healthcar inform technolog
brightre busi recent acquisit
juli acquisit
electron health record softwar bill
code servic well advanc analyt
home health hospic agenc
juli agre form joint
ventur verili think joint
ventur could acceler awar sdb
commenc oper joint
ventur dec quarter initi
expect gross margin
year-over-year continu manufactur
procur effici
partial off-set typic price declin
hold recommend reflect
view share trade forward
earn near intrins valu despit
continu price pressur
continu report increas sale volum
continu adopt solut
outsid north america weak dec
quarter rais concern rate
adopt sdb devic
launch new product increasingli
gener track patient complianc
next-gener ventil believ
command price premium
technolog capabl product
also expect sustain momentum
awar sdb increas
risk recommend target price
liabil reduc reimburs
willing third-parti payer
target reflect
multipl ep
estim multipl high
end rang
recent product launch shift toward
fiscal year end jun ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
resm inc engag develop manufactur distribut medic equip
treat diagnos manag sleep-disord breath sdb respiratori disord
compani portfolio product treatment obstruct sleep apnea osa form
sdb includ airflow gener diagnost product mask system headgear accessori
produc continu posit airway pressur cpap variabl posit airway pressur vpap
autoset system titrat treatment sdb flow gener system deliv posit airway
pressur patient interfac either small nasal mask nasal pillow system full-fac mask
compani vpap unit deliv bi-level therapi market sleep record diagnosi
treatment sdb sleep clinic hospit
cpap vpap bi-level air flow gener account approxim fy jun total
revenu mask accessori motor diagnost product account recent
acquir brightre account remain
compani diagnost system record relev respiratori sleep data analyz
sleep specialist physician modifi appropri osa treatment regimen patient
assist profession diagnos manag treatment patient data
commun control product reslink rescontrol rescontrol ii txcontrol resscan
restraxx modul facilit transfer data inform flow
gener compani market variou product accessori includ humidifi
humidair connect directli cpap vpap autoset flow gener
humidifi heat air deliv patient option accessori includ cold passov
humidifi carri bag breath circuit
offer product north america latin america wholly-own subsidiari austria
finland franc germani spain sweden norway netherland switzerland unit kingdom
also wholli own subsidiari australia hong kong japan new zealand singapor china
india product market countri sleep clinic home health care dealer
compani competitor includ philip bv devilbiss divis sunris medic inc nellcor puritan
bennett divis covidien ltd fisher paykel healthcar corpor limit princip
intern competitor philip devilbiss nellcor puritan bennett addit product
compet surgic procedur dental applianc design treat osa- sdb-relat
see growth sdb market futur attribut posit number
factor includ increas awar osa improv understand role sdb treatment
manag cardiac neurolog metabol relat disord increas home-bas
diagnosi strategi busi oper develop toward effort capit
plan sdb market growth includ follow critic compon continu product
develop innov expans geograph presenc increas public clinic
awar expans new clinic applic leverag experi manag
fy spent million approxim net revenu million
fy compani seek new applic technolog current focu area
hypertens stroke congest heart failur chf chronic obstruct pulmonari diseas copd
develop devic treat cheyne-stok breath patient chf
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
take control hous
repres think see
significantli lower level effort
republican trump administr
tri repeal
hospit spend larg driver medic
equip sale robust
strong economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index rose vs declin
fundament outlook health care
equip sub-industri next month
neutral slightli posit continu
expect compani sub-industri
grow posit macro environ
compani gener benefit
laxer food drug administr fda
technolog advanc sub-industri
also mani product area
equip use non-elect procedur
howev valuat high industri
investor sentiment medic devic
compani appear shaken
volatil late think
higher valuat sub-industri
mostli warrant recent expand
margin robust revenu growth weaker
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess headwind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
although chines
govern seek lower health care cost
equip manufactur insul
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep estim compar ten-year histor averag price-to-earnings
modest premium peer reflect improv sale earn growth
outlook increas fy fy ep estim
report dec-q oper ep vs
consensu dec-q sale increas growth
canada latam market strong adopt product
expect sale growth fy aid new product /keith snyder
et cfra maintain hold opinion share inc
rais target price fy
june ep estim multipl slight discount peer
reflect slower organ sale growth outlook expect limit
margin expans rais fy ep estim
report sep-q oper ep vs line consensu
sep-q sale increas growth emea america
region well contribut brightre acquisit see
sale growth fy aid strong demand new mask /keith snyder
analyst research note compani news
et cfra maintain hold opinion share resm inc
lower target
ep estim toward high end three-year price-to-earnings rang
dec-q ep vs higher
estim lower june ep estim
ep dec-q sale increas constant currenc
million sale america exclud saa grew year-over-year
sale europ asia market grew constant currenc
basi expect devic sale declin constant currenc
term manag refrain provid detail commentari factor
drive weaker-than-expect devic growth continu expand
invest digit health dec-q compani acquir propel
propel offer platform help doctor better manag chronic
obstruct pulmonari diseas copd asthma /kevin huang cfa
et cfra maintain hold opinion share inc
lift target above-p
ep estim technolog leader
under-penetrated sleep apnea market sep-q ep vs
higher estim keep fy jun ep estim rais
fy ep sep-q sale increas constant
currenc million sale america exclud saa grow
year-over-year sale europ asia market grow
constant currenc basi expect incom center medicar
competit bid program posit patient healthcar
provid compani also seen posit reimburs chang
sever countri past month franc japan toward
digit health technolog expect grow global accept benefit
lift target above-p
ep estim technolog leader
under-penetr sleep apnea market jun-q ep vs
higher estim rais fy jun ep
initi fy ep jun-q sale increas constant
currenc million sale america grow
year-over-year sale europ asia market grow
constant currenc gross margin jun-q rel flat vs
prior-year period reflect typic price pressur larg
off-set manufactur procur effici think robust
growth opportun continu deliv innov launch
quietair technolog jun-q plan scale launch
maintain target above-p
next-twelve-month ep estim technolog leader
under-penetrated sleep apnea market mar-q ep vs
higher estim rais june ep
ep mar-q sale increas
million america grow europ asia combin see
growth mar-q unveil launch portabl oxygen
concentr smartphon app screen sleep apnea china
mar-q encourag rmd brightre software-as-a-servic
busi aim enabl better patient care complianc
roughli total revenu grew year-on-year howev
continu success awar sleep disord breath
increas larger competitor resourc dispos could
becom interest sleep apnea market /kevin huang
rais target fy june
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
